NASDAQ-listed Akari Therapeutics PLC –which has a pipeline of tick-derived molecules selected to suppress mediators of chronic inflammation in wide range of orphan disorders – expects a Phase II topline data readout soon for its lead candidate that it hopes will open the way for Phase III trialing later this year in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH).
Akari’s lead molecule is Coversin, a recombinant small protein (16,740 Da) derived from a native protein discovered in the saliva of the Ornithodoros moubata tick
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?